Neimeth International Pharmaceuticals plc announced earnings results for the year ended September 30, 2013. For the period, the company reported a turnover of NGN 2,017 billion as against NGN 1,519 billion (adjusted to 12 months) in 2012, showing a growth indices of 33%. With top line revenue of NGN 2,017 billion the company showed an impressive gross margin of NGN 642 million, a growth of 21% over 2012's NGN 529 million (adjusted to 12 months) Profit before tax showed a significant growth of 451%, NGN 183 million, against NGN 52 million in 2012.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 NGN | -0.63% | +3.25% | -18.04% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.04% | 4.59M | |
+51.54% | 795B | |
-7.20% | 350B | |
+18.67% | 328B | |
+7.48% | 294B | |
+17.61% | 245B | |
+1.06% | 222B | |
+11.21% | 215B | |
+3.64% | 160B | |
-3.96% | 157B |
- Stock Market
- Equities
- NEIMETH Stock
- News Neimeth International Pharmaceuticals Plc
- Neimeth International Pharmaceuticals plc announces Earnings Results for the Year Ended September 30, 2013